归属结果暨股份上市的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-077 重要内容提示： 1、本次归属的限制性股票上市流通日：2025 年 10 月 27 日，本 次归属的第二类限制性股票不设限售期； 2、本次办理归属的限制性股票数量为 437,691 股，占公司总股 本（剔除回购股份，下同）0.66%； 3、本次归属的激励对象人数：41 人； 4、本激励计划股票来源为公司向激励对象定向发行的本公司人 民币 A 股普通股股票。 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开了第三届董事会第十四次会议，审议通过了《关 于 2023 年限制性股票激励计划首次授予部分第二个归属期归属条件 成就的议案》，董事会认为，公司 2023 年限制性股票激励计划（以 下简称"《激励计划》"、"本激励计划"）首次授予部分第二个归 广州迈普再生医学科技股份有限公司 关于 2023 年限制性股票激励计划首次授予第二个归属期 归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 归属结果暨股份上市的 ...

证券代码：301033 证券简称：迈普医学 公告编号：2025-080 广州迈普再生医学科技股份有限公司 关于公司与关联方签订产品销售代理合作协议的公告 签订产品代理合作协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 重大内容提示： 1、本次交易构成关联交易，不构成《上市公司重大资产重组管 理办法》规定的重大资产重组； 2、本次关联交易事项已经公司第三届董事会第十六次会议审议 通过，关联董事回避表决。 一、关联交易概述 根据公司业务发展需要，广州迈普再生医学科技股份有限公司 （以下简称"公司"）拟分别与关联方江西司托迈医疗科技有限公司 （以下简称"司托迈"）、江西远赛医疗科技有限公司（以下简称"远 赛医疗"）签订《产品代理合作协议书》，其中协议书分别约定，司 托迈委托公司独家代理销售"持续葡萄糖监测系统"产品，独家代理 期限自 2025 年 11 月 1 日起至 2026 年 12 月 31 日，代理期限内采购 预估含税金额为人民币 2,150 万元；远赛医疗委托公司独家代理销售 "超声软组织手术设备,一次性使用超声软组织手术刀头"产品，独 签订产 ...

增加日常性关联交易额度公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-079 广州迈普再生医学科技股份有限公司 关于增加公司 2025 年日常性关联交易额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 （一）日常关联交易预计情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第三届董事会第八次会议审议通过了《关于预 计公司 2025 年日常性关联交易的议案》。具体内容详见 2025 年 4 月 25 日公司披露在巨潮资讯网（http://www.cninfo.com.cn）上的《关 于预计公司 2025 年日常性关联交易的公告》（公告编号：2025-019）。 根据公司业务发展实际需求， 2025 年公司与广州见微医疗科技 有限公司（以下简称"见微医疗"）的日常性关联交易规模预计将超 出前次审议额度。为保障业务持续稳定开展，确保与见微医疗的合作 顺应业务发展节奏、满足实际经营需要，依据公司关联交易相关管理 规定，拟对上述日常性关联交易额度进行相应调整，预计增加日常性 ...

董事会决议公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-078 广州迈普再生医学科技股份有限公司 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （一）审议通过《关于增加公司 2025 年日常性关联交易额度的 议案》 根据公司业务发展实际需求，2025 年与广州见微医疗科技有限 董事会决议公告 公司（以下简称"见微医疗"）的日常性关联交易规模预计将超出前 次审议额度。为保障业务持续稳定开展，确保与见微医疗的合作顺应 业务发展节奏、满足实际经营需要，依据公司关联交易相关管理规定， 拟对上述日常性关联交易额度进行相应调整。 经审议，董事会认为：公司与关联方交易定价政策和定价依据遵 照公开、公平、公正的原则，双方交易价格按照市场价格结算，不会 对公司及公司财务状况、经营成果产生不利影响，不存在损害公司及 全体股东特别是中小股东利益的行为，公司主营业务不会因发生的关 联交易而对关联方形成依赖，没有影响公司的独立性。本议案在董事 会审议权限范围内，无需提交公司股东会审议。 表决结果：8 票 ...

Core Viewpoint - The company, Maipu Medical, announced its intention to sign product agency cooperation agreements with related parties, indicating a strategic move to expand its product offerings and sales channels in the medical technology sector [1] Group 1: Agreements and Financials - Maipu Medical plans to exclusively represent the sales of the "Continuous Glucose Monitoring System" for Jiangxi Sitomai Medical Technology Co., with an estimated procurement amount of 21.5 million yuan during the agency period [1] - The company will also exclusively represent the sales of "Ultrasound Soft Tissue Surgical Equipment" and single-use ultrasound soft tissue surgical knife heads for Jiangxi Yuansai Medical Technology Co., with an estimated procurement amount of 3.5 million yuan during the agency period [1]

Core Insights - The company reported a third-quarter revenue of 91.45 million yuan, representing a year-on-year increase of 32.74% [1] - The net profit for the third quarter was 28.55 million yuan, showing a year-on-year growth of 39.89% [1] - For the first three quarters, the total revenue reached 249 million yuan, reflecting a year-on-year increase of 30.53% [1] - The net profit for the first three quarters amounted to 75.85 million yuan, with a year-on-year growth of 43.65% [1]

广州迈普再生医学科技股份有限公司 广州迈普再生医学科技股份有限公司 2025 年第三季度报告 证券代码：301033 证券简称：迈普医学 公告编号：2025-081 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员) 声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 广州迈普再生医学科技股份有限公司 2025 年第三季度报告 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 91,450,561.18 | 32.74% | 249,228,235.32 | 30.53% | | 归属于上市公司股东 | 28, ...

Policy Developments - The State Administration for Market Regulation and the National Medical Products Administration conducted legislative research on the Medical Device Management Law, emphasizing the importance of scientific, democratic, and legal legislation to enhance the quality of laws and promote implementation [2] Drug and Device Approvals - East China Pharmaceutical's subsidiary received a drug registration certificate for Remabizine injection, which is used in conjunction with MediBeacon's device to assess patients' kidney function [4] - Kelun Pharmaceutical's subsidiary obtained approval for its targeted antibody-drug conjugate, Boduocizumab, for treating HER2-positive breast cancer patients who have received prior anti-HER2 therapies, showing significant improvement in progression-free survival [5] Financial Reports - Wowo Pharmaceutical reported a net profit increase of 179.34% year-on-year for the first three quarters, with revenues of 625 million yuan [7] - Pianzaihuang's third-quarter net profit decreased by 28.82% year-on-year, attributed to reduced sales in the pharmaceutical manufacturing sector and declining gross margins [8] Capital Market Activities - Weigao Blood Products is planning to acquire 100% of Shandong Weigao Purui Pharmaceutical Packaging Co., leading to a stock suspension for up to 10 trading days [11] - Hansoh Pharmaceutical entered a licensing agreement with Roche, potentially earning up to $1.45 billion in milestone payments for the development of HS-20110, a targeted antibody-drug conjugate for colorectal cancer [12][13] - Maipu Medical plans to acquire 100% of Guangzhou Yijie Medical Technology for 335 million yuan and raise additional funds [15] Industry Developments - Sanofi announced the launch of its insulin raw material project in Beijing, with a total investment of 1 billion euros, expected to be completed by 2032 [18]

Policy Developments - The State Administration for Market Regulation and the National Medical Products Administration conducted legislative research on the draft Medical Device Management Law, emphasizing the importance of scientific, democratic, and legal legislation to enhance the quality of laws and promote implementation [1] Drug and Device Approvals - East China Pharmaceutical's subsidiary received a drug registration certificate for Remabizine injection, which is used in conjunction with MediBeacon's device to assess patients' glomerular filtration rate [2] - Kelun Pharmaceutical's subsidiary obtained approval for its ADC product, Botuzumab, for treating HER2-positive breast cancer, showing significant improvement in progression-free survival compared to T-DM1 [3] Financial Reports - WoHua Pharmaceutical reported a net profit increase of 179.34% year-on-year for the first three quarters, with revenue of 625 million yuan [4] - Pianzihuang's third-quarter net profit decreased by 28.82%, with revenue down 26.28% year-on-year, attributed to reduced sales in the pharmaceutical manufacturing sector [5] Capital Market Activities - Weigao Blood Products is planning to acquire 100% of Shandong Weigao Puri Pharmaceutical Packaging Co., leading to a stock suspension for up to 10 trading days [7] - Hansoh Pharmaceutical entered a licensing agreement with Roche, potentially earning up to $1.45 billion in milestone payments for the development of HS-20110, a targeted ADC for colorectal cancer [8] Industry Developments - Sanofi announced the launch of its insulin raw material project in Beijing, with a total investment of 1 billion euros, expected to be completed by 2032 [12]

Core Viewpoint - Myp Medical is expanding its presence in the neuro-interventional medical supplies sector by acquiring 100% of Guangzhou Yijie Medical Technology Co., Ltd. for 335 million yuan, marking a significant step towards establishing a comprehensive solution for neurology departments [2][3]. Financial Performance - In the first half of 2025, Myp Medical achieved revenue of 158 million yuan, a year-on-year increase of 29.28%, and a net profit of 47.3 million yuan, up 46.03% [2][6]. - The company reported a gross margin of 80.59% in the first half of 2025, an increase of 1.74 percentage points compared to the same period last year [6][7]. - From 2019 to 2023, the compound annual growth rate (CAGR) of net profit was 10%, with a notable acceleration in 2024, where revenue reached 278 million yuan, a 20.61% increase year-on-year [6][7]. Research and Development - Myp Medical's R&D investment reached 19.29 million yuan in the first half of 2025, a significant increase of 58.95% year-on-year, with total R&D expenditure from 2020 to the first half of 2025 amounting to 206 million yuan [6][7][8]. - The company holds 259 domestic patents and 30 international patents, with 178 of them being invention patents [8]. Acquisition Details - The acquisition of Yijie Medical will be financed through a combination of share issuance and cash payment, with the transaction price determined through negotiations involving third-party evaluators to ensure fairness [3][4]. - Yijie Medical specializes in neuro-interventional products, having established a product line that includes key devices such as neuro-interventional catheters and guidewires, which are already approved for sale in over 200 top-tier hospitals [3][4]. Strategic Implications - The acquisition is expected to enhance Myp Medical's market competitiveness in neurology by integrating its product lines and leveraging technological and channel synergies, thereby accelerating the domestic substitution of high-value medical supplies [5].